Your browser doesn't support javascript.
Safety of Global SARS-CoV-2 Vaccines, a Meta-Analysis.
Chen, Linyi; Cai, Xianming; Zhao, Tianshuo; Han, Bingfeng; Xie, Mingzhu; Cui, Jiahao; Zhang, Jiayu; Wang, Chao; Liu, Bei; Lu, Qingbin; Cui, Fuqiang.
  • Chen L; Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China.
  • Cai X; Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China.
  • Zhao T; Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China.
  • Han B; Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China.
  • Xie M; Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China.
  • Cui J; Faculty of Medicine, Imperial College London, London SW7 2AZ, UK.
  • Zhang J; Bioinformatics Program, School of Science, Xi'an Jiaotong-Liverpool University, Suzhou 215123, China.
  • Wang C; Department of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing 100191, China.
  • Liu B; Department of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing 100191, China.
  • Lu Q; Department of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing 100191, China.
  • Cui F; Department of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing 100191, China.
Vaccines (Basel) ; 10(4)2022 Apr 12.
Article in English | MEDLINE | ID: covidwho-1786105
ABSTRACT
(1)

Background:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines were developed in only a short amount of time and were widely distributed. We conducted this meta-analysis to understand the safety of SARS-CoV-2 vaccines. (2)

Methods:

We searched the corresponding literature published from 1 January 2020 to 20 October 2021. Information of adverse events (AEs) of each selected work was collected. The quality and bias of studies was evaluated, and meta-analysis was carried out by using Stata 17.0. (3)

Results:

Totally, 11,451 articles were retrieved, and 53 of them were included for analysis. The incidence rate of AEs was 20.05-94.48%. The incidence rate of vascular events increased after viral vector vaccination, while the incidence rate of vascular events decreased after mRNA vaccination. Viral vector vaccine had a higher AE rate compared to mRNA vaccines and inactivated vaccines. In most circumstances, the incidence of AEs was higher in older people, female and after the second dose. The sensitivity of meta-analysis was acceptable; however, the literature was subject to a certain publication bias. (4)

Conclusions:

The safety of SARS-CoV-2 vaccines was acceptable. The incidence of allergic symptoms and cardiovascular and cerebrovascular symptoms was low. Viral vector vaccine had a higher risk of leading to thrombosis events. The understanding of SARS-CoV-2 vaccine AEs should be enhanced, so as to promote the vaccination.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Reviews Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10040596

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Reviews Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10040596